Raphael Mechoulam, le père des cannabinoïdes est décédé

Raphael Mechoulam, the father of cannabinoids, has died

For the past few days, cannabis consumers and people around the world who use its derivatives have been paying tribute to a man whose contribution to the discovery of cannabis’s active compounds changed the history of this age-old plant. Dr Raphael Mechoulam, chemist and scientist, has died in Israel at the age of 92, leaving behind an invaluable scientific legacy.


Raphael Mechoulam’s work includes his contribution to the isolation of delta-9 tetrahydrocannabinol (THC), the main psychoactive compound in cannabis. But the chemist is also credited with discovering cannabidiol (CBD), a non-psychoactive molecule with promising therapeutic properties.


A professor at the School of Pharmacy at the Hebrew University of Jerusalem, Raphael Mechoulam devoted more than forty years of his life to studying the cannabis plant and its medical uses. A small man with a cheerful voice, he became a leading supporter of the international cannabis community, sharing his knowledge with people around the world. In this article, we look back at Raphael Mechoulam’s contributions to cannabis science, as well as his impact on today’s industry and research.


Who was Raphael Mechoulam, and what was his role in the history of CBD?

Raphael Mechoulam was an Israeli chemist and scientist who played a crucial role in the history of cannabis research. Born in Sofia, Bulgaria, in 1930, he grew up in Israel and earned his doctorate in organic chemistry from the Hebrew University of Jerusalem in 1958.
 

In the 1960s, while working as a professor at the university’s School of Pharmacy, Raphael Mechoulam became interested in the cannabis plant and its active compounds. In 1963, he became the first scientist to isolate delta-9 tetrahydrocannabinol (THC), the plant’s main psychoactive compound.
 

However, it was not just the discovery of THC that made Raphael Mechoulam an important figure in the history of cannabis. He is also known for isolating and identifying cannabidiol (CBD) in 1963, a non-psychoactive molecule found in cannabis.
 

His research helped improve understanding of the pharmacological effects of THC and CBD on the human body, paving the way for numerous studies into the potential medical uses of these compounds.
 

Raphael Mechoulam therefore played a key role in the scientific recognition of cannabis as a medicinal plant, helping to pave the way for a market for cannabis for medical and recreational use. His discovery of CBD, in particular, sparked considerable interest in medical research into its anti-inflammatory, analgesic and anti-epileptic properties, among others.

The discovery of CBD: how did Raphael Mechoulam identify the properties of this molecule?

As mentioned above, Raphael Mechoulam is known for isolating and identifying cannabidiol (CBD) in 1963. He made this discovery in collaboration with Yechiel Gaoni, another researcher at the Hebrew University of Jerusalem.


To isolate CBD, Mechoulam and Gaoni used a technique called reverse-phase chromatography, which separates the components of a mixture according to how they interact with a column containing a specific substance. They then used mass spectrometry to identify the isolated components.


The discovery of CBD was significant because it showed that this molecule, unlike THC, does not have psychoactive effects. This finding helped improve understanding of how cannabis affects the human body and paved the way for numerous studies into the potential medical uses of CBD.


Raphael Mechoulam went on to conduct several studies into the pharmacological effects of CBD, including its anti-inflammatory, analgesic and anti-epileptic properties. In the 1980s, he discovered that CBD could be used to treat epilepsy in children, sparking considerable interest in the molecule within the medical community.


More recently, Raphael Mechoulam’s research has shown that CBD could also be used to relieve symptoms of conditions such as anxiety, depression, chronic pain and even cancer.


In summary, Raphael Mechoulam’s discovery of CBD was an important step in the scientific recognition of cannabis as a medicinal plant. His research into this molecule paved the way for numerous studies into the potential medical uses of cannabis and helped bring about a market for CBD for medical and recreational use.

The medical applications of CBD: has Raphael Mechoulam’s research opened up new therapeutic possibilities?

Raphael Mechoulam’s research into the medical applications of CBD has been very promising and has attracted considerable interest within the medical community. Here are some of the most important findings from his research:

CBD for the treatment of epilepsy

One of the most interesting medical applications of CBD is its use in the treatment of epilepsy. In 1980, Raphael Mechoulam conducted a study showing that CBD could reduce seizures in children with epilepsy. Since then, numerous studies have been carried out on the use of CBD to treat epilepsy, with very encouraging results.

CBD for reducing anxiety and depression

CBD has also been studied for its potential to reduce anxiety and depression. Studies have shown that CBD could help reduce anxiety symptoms in patients with anxiety disorders such as panic disorder, obsessive-compulsive disorder and post-traumatic stress disorder. Similarly, studies have shown that CBD could help reduce symptoms of depression in patients with depression.

CBD for reducing chronic pain

CBD has also been studied for its potential to relieve chronic pain. Studies have shown that CBD could indeed help reduce pain in patients with chronic pain conditions such as neuropathic pain, arthritic pain and cancer-related pain.

CBD for relieving cancer symptoms

Finally, CBD has also been studied for its potential to relieve cancer symptoms. Although research into CBD and cancer is ongoing, CBD has been shown to help reduce the growth of cancer cells in laboratory animals.

The impact of Raphael Mechoulam’s research on the cannabis industry: how did the discovery of CBD influence the market for cannabis products?

The discovery of CBD had a considerable impact on the cannabis industry and opened up new possibilities for cannabis products. Here are some ways Raphael Mechoulam’s research has affected the cannabis industry:

CBD-derived products

The discovery of CBD led to an explosion in CBD products on the market. These products can be used to relieve pain, anxiety, inflammation and other conditions. CBD products are now commonplace in health food shops, pharmacies, specialist shops and even supermarkets.

CBD regulation

The discovery of CBD has also had an impact on cannabis regulation. In many countries, CBD is legal while THC is not. This has opened up new markets for cannabis-based products. However, CBD regulation is complex and varies from one country to another. In addition, the cannabis industry is still subject to extensive regulation and oversight, which can make the production and distribution of cannabis-based products more challenging.

The future prospects for the cannabis industry

The discovery of CBD has also opened up new prospects for the cannabis industry. Raphael Mechoulam’s research showed that cannabis had considerable therapeutic potential. Future research could therefore lead to new medical applications for cannabis, as well as new cannabis-based products. For example, research is under way into the use of cannabis to treat conditions such as multiple sclerosis, cancer and epilepsy.


In conclusion, Raphael Mechoulam’s discovery of CBD had a considerable impact on the cannabis industry. It led to an explosion in the number of CBD-based products on the market, influenced cannabis regulation and opened up new prospects for medical treatments within the cannabis industry.

Raphael Mechoulam, a researcher dedicated to his work until the end

Raphael Mechoulam was a passionate researcher who devoted his life to medical cannabis research. Even at an advanced age, he continued to innovate and develop new therapies to help patients suffering from a range of conditions. At the CannMed cannabis conference in California in 2019, Mechoulam announced the creation of a new, synthetically stable cannabidiol acid (CBDA), suitable for clinical use.
 

By synthesising the unstable acid molecules found in the cannabis plant, Mechoulam created a stable, consistent basis for researching new therapies for a wide range of medical needs. This paves the way for new therapeutic prospects for patients suffering from various conditions, such as epilepsy.
 

However, Mechoulam was also aware of the research time already lost and of the patients who had been unable to benefit from cannabis-based treatments for their conditions. He urged the scientific community to provide greater support for medical cannabis research and lamented the fact that thousands of children could not be helped in time.
 

In 2000, Mechoulam received the Israel Prize for Exact Sciences – Chemistry for his contributions to science, and in 2011, he received the NIDA Discovery Award. In 2019, he was awarded the Harvey Prize for his breakthroughs in science and technology.
 

Mechoulam’s discovery of synthetically stable cannabidiol acid marks a major advance in medical cannabis research and bears witness to his commitment to discovering new therapies to help patients in need.